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The discovery of interleukin (IL)-17-producing CD4þ T (Th17)
cells as a unique T-helper cell lineage has revised our
understanding of T-cell-mediated tissue injury. Recent data
from studies in humans and mice indicate that autoimmune
diseases such as multiple sclerosis and rheumatoid arthritis,
classically believed to be Th1-mediated, are predominantly
driven by a Th17 immune response. IL-17 (IL-17A), IL-17F,
IL-21, IL-22, and possibly also IL-9 produced by Th17 cells
promote inflammation by directly causing tissue injury and
enhancing secretion of pro-inflammatory cytokines and
chemokines by resident cells. This results in augmented
infiltration of leukocytes, in particular neutrophils, to the
affected tissue where they induce organ inflammation and
injury. Recent studies have highlighted the potential
importance of the Th17 immune response also in renal
inflammatory disease. This includes the identification and
characterization of IL-17-producing T cells in nephritic
kidneys of mice and humans, as well as evidence for the
contribution of IL-17 and the IL-23/Th17 axis to renal tissue
injury in glomerulonephritis. In this review, we will briefly
summarize general characteristics of Th17 cells and discuss in
detail the potential role of the Th17 immune response in
human and experimental renal inflammation with a special
focus on glomerulonephritis.
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DIFFERENTIATION AND FUNCTION OF TH17 CELLS
CD4þ T-helper cells have a central role in the regulation of
the adaptive immune response. Although activation of
CD4þ T-helper cells is critical for the control and
elimination of a wide array of invading pathogens, auto-
immune disease can arise if CD4þ T cells become
erroneously activated in response to self-antigens. One of
the key mechanisms used by the immune system to prevent
autoimmunity is thus to precisely regulate the activation and
differentiation of CD4þ T-helper cells.1
Based on their cytokine secretion profile and expression of
specific transcription factors, CD4þ T cells are today
classified into four major subsets: Th1, Th2, Th17, and
regulatory T cells (Tregs), although further T-helper cell
lineages might exist.2
First evidence for the heterogeneity of CD4þ T cells
derived in 1986 from the seminal work by Robert Coffman
and Tim Mosmann who proposed that CD4þ T cells can be
subdivided into two independent subsets, called T-helper 1
cells (Th1) and T-helper 2 cells (Th2).3 Th1 cells mainly
produce interferon-g (IFN-g), which is essential for macro-
phage activation, and are predominantly involved in the
clearance of intracellular pathogens. In contrast, Th2 cells are
characterized by the production of interleukin (IL)-4, IL-5,
and IL-13 and are critical for IgE production, eosinophil
recruitment, and participate in the elimination of extra-
cellular pathogens and parasites. IL-12 mainly produced by
antigen-presenting cells is critical for Th1 differentiation
whereas IL-4 has the major role in Th2 differentiation. Data
from humans and experimental models provided strong
evidence that Th1 cells are also involved in cell-mediated
autoimmune disease (for example, multiple sclerosis, Crohn’s
disease, rheumatoid arthritis, and crescentic glomerulone-
phritis) whereas Th2 cells have been associated with allergic
diseases.
The concept that the Th1 immune response is of central
importance in development of autoimmunity was challenged
by the observation that animals lacking the ability to mount a
functional Th1 response due to IFN-g or IL-12 deficiency still
develop significant and occasionally even exacerbated experi-
mental arthritis and autoimmune encephalomyelitis. These
effects were subsequently explained by the discovery of a
highly pathogenic IL-17-producing CD4þ effector T-cell
subset, termed Th17. Th17 cells differ from Th1 and Th2 cells
not only by their cytokine expression profile, but also by the
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cytokines that drive their differentiation. Under the
influence of IL-6, transforming growth factor-b (TGF-b),
IL-1, and IL-21 the key transcription factors RORgt,
RORa, and STAT3 are induced and mediate Th17 cell
differentiation in mice and humans.2 Remarkably, recent
studies indicate that there might be also TGF-b-independent
pathways for differentiation of Th17 cells.4 At later stages,
IL-23 is essential for stabilization and expansion of the Th17
cell population. An overview of the differentiation factors
and effector functions of CD4þ T-cell subsets is shown in
Figure 1.
The contribution of Th17 cells to autoimmune disease was
first shown in mice deficient for the IL-23 subunit p19 (IL-
23p19).5 IL-23p19/ animals mount normal Th1 responses
but have substantially reduced numbers of Th17 cells. Most
importantly, these mice were resistant to the development of
experimental autoimmune encephalomyelitis5 and collagen-
induced arthritis,6 models resembling human multiple
sclerosis and rheumatoid arthritis. Likewise, IL-17-deficient
mice also developed less severe autoimmune disease,
providing further evidence for the functional importance of
the Th17 immune response.7
Th17 cells promote inflammation by the secretion of IL-17
(also called IL-17A), IL-17F, IL-21, IL-22, and tumor necrosis
factor a (TNF-a) leading to upregulated expression of
numerous pro-inflammatory cytokines and chemokines such
as IL-6, CXCL1, CXCL8, and CCL2 by local tissue and
infiltrating inflammatory cells. These inflammatory media-
tors further enhance the recruitment of different leukocyte
subsets, predominantly neutrophils, ultimately leading to
target organ injury.
IL-17 was isolated and characterized 10 years before
identification of the Th17 lineage from a rodent CD4þ T-cell
cDNA library.8 It represents the founder member of a
cytokine family that includes IL-17, IL-17B, IL-17C, IL-17D,
IL-17E, IL-17F (also called IL-25) and the five receptors
IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE.9 The best
characterized and biologically most potent member of the
family is IL-17A, which binds to the IL-17RA and IL-17RC.
The primary function of the Th17 immune response is in
the defense against infections by extracellular bacterial and
fungal pathogens.10,11 The presence of IL-17-producing
T cells in biopsies of patients with Crohn’s disease, multiple
sclerosis, and rheumatoid arthritis suggests that the Th17
immune response also contributes to tissue injury in human
inflammatory and autoimmune disease.12 However, numbers
of IL-17-producing T cells at the site of inflammation are
usually low and they are often found together with a more
prominent infiltrate of Th1 cells. This suggests that the
combined action of pathogenic Th1 and Th17 cell subsets
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Figure 1 |Differentiation of CD4þ T-cell subsets. After the encounter of antigen and co-stimulatory molecules presented by antigen-
presenting cells, naive CD4þ T cells can differentiate into different subpopulations. The lineage commitment of CD4þ T cells depends on
the cytokine milieu accompanying the T-cell activation process in secondary lymphoid organs. The diverse T-helper cell subtypes show
differential activation of transcriptional programs and are characterized by secretion of certain effector cytokines that enable them to
provide protection against different classes of pathogens and to mediate autoimmunity. IFN-g, interferon-g; IL, interleukin; TGF-b, transforming
growth factor-b; Th1, T-helper 1 cell; TNF-a, tumor necrosis factor-a.
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might be responsible for establishment of full-blown auto-
immunity in humans.
TH17 CELLS IN EXPERIMENTAL NEPHRITIS
First evidence for contribution of IL-17 to inflammatory
reactions in the kidney comes from an in vitro study on
tubular epithelial cells that was published in 1998 more than
7 years before the discovery of Th17 cells in 2005.13 This
study shows that IL-17 contributes to the induction of an
inflammatory milieu in the kidney by stimulating the
production of IL-6, CXCL8, and CCL2 in primary cultures
of human proximal tubular epithelial cells (Figure 2).
Anticipating future concepts, the authors identify activated
T cells as the major source of IL-17 in the kidney.13 Almost
10 years after this initial publication, Th17-polarized CD4þ
T cells were first identified and characterized in the kidney
during renal inflammation.14 Using flow cytometric analyses
combined with intracellular cytokine staining, Dong and
Griffin showed presence of an IL-17-producing CD4þ T-cell
subset in murine kidneys after ureteral obstruction. These
cells displayed an activated memory phenotype and could be
readily stimulated to produce high levels of the effector
cytokine IL-17, indicating that these lymphocytes had
undergone prior differentiation.14 Although the authors
thoroughly characterized this newly identified intrarenal
T-cell subset, they did not investigate the functional
significance of these cells.
The initial evidence for functional importance of Th17
cells in renal inflammation was provided in 2009 in a murine
model of crescentic glomerulonephritis.15 Analysis of ne-
phrotoxic nephritis in IL-23p19 and IL-17 knockout mice
showed attenuated renal pathology and preserved renal
function in both strains, despite an intact Th1 response.
Consistent with the early studies on human tubular epithelial
cells, the effector cytokine IL-17 (alone or in synergy with
TNF-a) induced expression of monocyte and Th1 cell-
attracting chemokines in murine mesangial cells,15 providing
a possible mechanism for Th17-induced renal injury
(Figure 2).
Further support for involvement of the IL-23/Th17 axis in
renal autoimmunity comes from a simultaneous study in
experimental autoimmune glomerulonephritis, a mouse
model for Goodpasture’s syndrome.16 Using different mouse
strains with deficiency in IL-23, IL-12, and combined
deficiency of both cytokines, the group of Kitching and
Holdsworth dissected the separate roles of IL-23 (Th17-
associated) and IL-12 (Th1-associated) in the systemic
immune response to the Goodpasture antigen. Knockout of
IL-23, but not IL-12, led to reduced proliferation and
activation of T and B cells in secondary lymphoid organs and
reduced cytokine and antibody production by immune cells,
resulting in protection from immune-mediated kidney
injury.16 In a subsequent study, the same group of
investigators showed that both Th1 and Th17 cells can
mediate renal injury.17 Differences in immunopathology
induced by the two T-cell subsets were assessed by the
transfer of antigen-specific Th1 or Th17 cells (polarized
in vitro) into mice with the T-cell antigen planted on the
glomerular basement membrane. Interestingly, the time
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Figure 2 |Current pathophysiological concept of Th17-mediated
kidney injury. Infiltrating Th17 cells secrete IL-17 (also called IL-17A)
that stimulates resident renal cells through the IL-17 receptor to
produce chemokines and other inflammatory mediators. IL-17
induces expression of a specific chemokine pattern that primarily
leads to the recruitment of neutrophils, but also includes monocyte-
and Th1-cell-attracting chemokines. Furthermore, Th17 cells might
facilitate the infiltration of additional Th17 cells directly by secretion
of the chemokine CCL20 and indirectly by stimulating resident cells
to produce CCL20. Recruitment of the other pro-inflammatory
leukocyte subsets ultimately leads to the progression of immune-
mediated kidney damage. IL, interleukin; Th1, T-helper 1 cell.
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kinetic and predominance of certain cellular and soluble
effectors were different in Th1 cell- and Th17 cell-injected
animals. Although Th17 cells induced expression of CXCL1,
neutrophil recruitment, and early renal injury, Th1 cell-
recipients showed more CCL2 and CCL5, along with
increased macrophage activity and renal injury at later time
points.17 Finally, the same group showed a crucial role for
IL-17 in mediation of renal tissue damage in a murine model
of vasculitis induced by the autoantigen myeloperoxidase.
Importantly, IL-17 knockout mice were protected from
kidney injury due to impairment of both, the innate and
the adaptive arms of the immune response (Gan et al.,18
2010). A potential cross-regulation between Th1 and Th17
cells was shown by a study that examined the development of
nephrotoxic nephritis in T-bet-deficient mice, lacking a
functional Th1 response.19 Despite an increased renal and
splenic expression of IL-17, presumably due to increased
numbers of Th17 cells, T-bet-deficient mice showed attenu-
ated nephritis, indicating that Th1 cells might be required for
full pathogenicity of Th17 cells in this model.
In another murine model of renal autoimmune disease,
the MRL-Faslpr model of lupus nephritis, a considerable
percentage of IL-17-producing T cells seem to belong to a
unique population of CD4 CD8 double-negative T cells that
are selectively expanded in these lupus-prone mice.20
Immunohistochemical co-staining of the pan T-cell marker
CD3 and IL-17 revealed that the tubulointerstitial infiltrates
of these mice with lupus nephritis contained CD3þ IL-17þ
cells, suggesting a role in renal injury. Furthermore, renal
autoimmune disease could be transferred to lymphocyte-
deficient hosts by injection of IL-23-treated cells from B6-
Faslpr lymph nodes that contain high percentages of double-
negative IL-17þ T cells.20 The potential contribution of Th17
cells to pathogenesis of lupus nephritis was supported by
examination of another lupus-prone mouse strain (New
Zealand BlackNew Zealand White F1 mice).21 The absence
of both TNF receptors (TNFR1 and TNFR2) in these lupus-
prone mice resulted in accelerated renal disease in combina-
tion with increased numbers of memory Th17 cells in the
spleen, indicating a role for TNF signaling in regulation of
the systemic Th17 response. Additional evidence for Th17
pathogenicity came from another study in the MRL-Faslpr
model that showed ‘classical’ CD4þ IL-17þ T cells also
contribute to the IL-17-producing T-cell subset in the kidney
of lupus-prone mice.22 In this study, the chemokine receptor
CXCR3 was identified as an important trafficking receptor
not only for Th1 cells, but also for Th17 cells, making it an
attractive target for treatment of T-cell-mediated autoim-
mune disease.22 As further characterization of intrarenal
Th17 cells in nephrotoxic nephritis revealed that the
chemokine receptor CCR6 also contributes to kidney-
directed migration of Th17 cells (Turner et al.,23 2010), this
trafficking receptor represents another potential target for
inhibition of the Th17 response in renal autoimmunity.
Another therapeutic approach for modulation of systemic
and renal Th17 response was suggested by a recent study that
showed downregulation of Th17-related gene products in
renal lymph nodes and kidneys of nephritic mice treated with
the HMG-CoA reductase inhibitor atorvastatin.24
Very recently, an additional role of IL-17 as a mediator of
innate immunity in kidney disease has been shown.25
Detailed studies in the kidney ischemia and reperfusion
model have identified murine neutrophils as an early source
of IL-17 in renal inflammation. This and other studies26
suggest that a wider spectrum of cell types contribute to
IL-17 production in vivo than previously thought.
TH17 CELLS IN HUMAN RENAL INFLAMMATION
Early studies in renal transplant recipients indicated that
IL-17 might have a role for the inflammatory response during
allograft rejection. IL-17 mRNA and protein could be
detected in rejecting renal allografts, whereas pretransplant
biopsies and normal kidneys were negative.13,27 Furthermore,
IL-17 mRNA expression in mononuclear cells of the urine
sediment distinguished patients with borderline rejection
from patients without signs of acute rejection in the renal
biopsy,27 identifying it as a possible marker for subclinical
allograft rejection.
Currently, there is only limited evidence for an involve-
ment of IL-17 in the pathogenesis of renal autoimmunity in
humans. A number of studies, however, suggest a potential
role of the Th17 axis. Freshly isolated peripheral blood T cells
of patients with systemic lupus erythematodes (SLE) contain
a higher percentage of IL-17þ T cells compared to healthy
controls.28 As in the MRL-Faslpr model of human SLE, a
population of CD4 CD8 double-negative T cells contributes
to the IL-17þ population in these patients. Furthermore,
sporadic IL-17þ CD3þ cells are found in the tubulointer-
stitial infiltrates in kidney biopsies from patients with lupus
nephritis.28 As predicted from the relative rareness of Th17
cells in human peripheral blood and the inflamed kidney,
measurement of total IL-17 in serum and urine of SLE
patients have produced inconsistent results.29,30 Although
lupus patients show a moderate increase in serum IL-17
protein compared to healthy individuals, there was no
correlation of the serum cytokine levels with disease activity
scores, renal involvement, or any other specific organ
involvement.29 In a separate study, another group of
investigators showed upregulation of IL-17 mRNA expression
in the urine sediment of patients with SLE.30 Remarkably,
this upregulation was also present in patients without renal
involvement and, moreover, the presence of active lupus
nephritis was correlated with a significant decrease of urinary
IL-17 mRNA.30 Most recently, elevated serum levels of IL-17
and IL-23 were also reported in patients with systemic
antineutrophil cytoplasmic antibody-associated vasculitis.31
However, this increase of circulating Th17-associated cyto-
kines was again not significantly correlated with active
disease. Taken together, it is conceivable that putative
pathogenic alterations of the Th17 response in human
autoimmunity can only rely on more elaborate detection
methods, than measurement of systemic IL-17 levels.
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A sophisticated approach to analyze IL-17 expression within
the kidney on a single-cell level was provided in a recent
study by Wang et al.32 Kidney-infiltrating cells were captured
from renal biopsies of patients with lupus nephritis by a laser
microdissection technique and subjected to nested reverse
transcriptase–PCR analysis for IL-17 and T-cell receptor
(TCR) mRNA expression. The percentage of IL-17þ TCRþ
cells within the kidney positively correlated with hematuria
and disease activity scores in lupus nephritis.32 However, the
complexity of this method, the mRNA-restricted approach,
and some inconsistencies within the experimental groups32
emphasize the necessity for further confirmation of these
promising results. In summary, further studies are clearly
needed to establish a potential link between Th17 cells and
the pathogenesis of SLE.
With regard to the Th17 response in other renal
inflammatory diseases, such as antineutrophil cytoplasmic
antibody-associated glomerulonephritis, Goodpasture’s syn-
drome, IgA nephropathy, or acute interstitial nephritis, there
are no data available, underlining the urgent need for further
research efforts in this field.
POTENTIAL THERAPEUTIC IMPLICATIONS
On the basis of the available human and experimental studies,
it is plausible that the development of renal autoimmune
disease cannot be clearly attributed to a single T-helper cell
subset. The character and stage of inflammatory kidney disease
are likely to be decisive for composition of the renal T-cell
infiltrate. Initial data implicate Th17 cells (and other IL-17-
producing leukocytes) as important early mediators of
inflammatory responses. Further studies are, however, neces-
sary to elucidate spatiotemporal aspects of the Th17 response in
the kidney. The cross-regulation between Th17, Th1, and Treg
cells, as well as the possibility of their interlineage conversion
within the target organ,33 represent two other important issues
in understanding of T-helper cell responses during renal
inflammation. Addressing these questions will help to identify
new therapeutic targets and to determine the optimal timing
for interference with the IL-23/Th-17 axis in renal disease.
As Th17 cells secrete a variety of potentially pathogenic
mediators, it seems a reasonable therapeutic strategy to
intervene upstream from the effector cytokine level. The use
of antibodies directed against p40, the shared subunit of
IL-23 and IL-12, allows simultaneous inhibition of both Th17
and Th1 cells.34 Currently, the two monoclonal antibodies
ustekinumab and ABT-874 have been tested in psoriasis,
Crohn’s disease, and multiple sclerosis. In phase 2 clinical
trials, both biologicals were effective in treatment of
moderate to severe psoriasis.34 In another recent study on
psoriasis patients, ustekinumab was even more effective
compared to the long approved therapy with TNF-a-
targeting substances.35 Ongoing clinical trials of ustekinumab
in Crohn’s disease have also been successful so far.34 In
contrast, the p40 antibody did not reduce the incidence of
demyelinating lesions in phase 2 clinical trials on patients
with relapsing-remitting multiple sclerosis.
Because evidence is accumulating that Th17 cells may not
be the only cellular source of IL-17 in early inflammatory
responses, which would presumably translate to a reduced
effectiveness of IL-23-targeted therapy, the blockade of the
effector cytokine IL-17 itself represents another therapeutic
approach. Preliminary data from human trials using anti-
IL-17 antibodies have shown promising results in treatment
of rheumatoid arthritis.34 Other experimental approaches to
therapeutically influence the Th17 response in autoimmunity
include the blockade of prostaglandins36 and osteopontin,37
as well as interference with target organ-directed trafficking
of Th17 cells by blockade of specific chemokine receptors.34
Interestingly, the blockade of the renin–angiotensin–
aldosterone system has also been shown to downregulate
the Th17 response and ameliorate autoimmune encephalo-
myelitis in mice.38,39
CONCLUDING REMARKS
The discovery of Th17 cells has substantially changed our view
of T-cell-mediated autoimmunity. To date, there is convincing
experimental evidence to support the notion that IL-17-
producing T cells contribute to kidney injury in renal
inflammatory diseases, such as glomerulonephritis and trans-
plant rejection. With respect to human disease, the findings
from animal models await further confirmation in larger patient
cohorts and additional entities of renal disease. Data from first
clinical trials in patients with ‘non-renal’ autoimmune disease
indicate that targeting of the IL-23/Th17 axis may evolve as a
promising therapeutic strategy in renal inflammation.
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